In this article, we will list the 5 Stocks Under $5 with Huge Upside Potential. Please visit 10 Stocks Under $5 with Huge Upside Potential if you would like to see the extended list and the methodology behind it.

5. ReNew Energy Global Plc (NASDAQ:RNW)

ReNew Energy Global Plc (NASDAQ:RNW) is one of the best stocks under $5 with huge upside potential. ReNew Energy Global Plc (NASDAQ:RNW) announced on April 15 that it has commissioned ~2.4 GW of assets in FY2026, taking its total operating capacity to ~12.6GW and making it the second largest in the country.

Management reported that this is after adjusting for 600MW of assets sold during the year as of March 31, 2026, adding that the commissioned capacity of 2.4 GW includes 1.75GW of solar, 0.62GW of wind, along with 25MW/100MWh of battery energy storage systems (BESS). ReNew Energy Global Plc (NASDAQ:RNW) also holds a fully constructed capacity of approximately 450MW, which is likely to be commissioned soon. As of March 31, 2026, the company’s gross capacity stands at ~20GW.

ReNew Energy Global Plc (NASDAQ:RNW) also reported that its portfolio, ReNew’s C&I arm, includes 2.5 GW of committed capacity, of which over 2.0 GW is already commissioned.

ReNew Energy Global Plc (NASDAQ:RNW) is a decarbonization solutions company involved in the research and development of renewable energy sources. The company’s operations are conducted through the following segments: Wind Power, Solar Power, Hydro Power, and Transmission Line.

4. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best stocks under $5 with huge upside potential. Chardan reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on April 10, setting a $16 price target on the stock. The rating update came after Replimune received a second complete response letter from the FDA for RP1 in combination with nivolumab in adults with unresectable advanced cutaneous melanoma who had progressed after anti-PD-1 therapy. The firm told investors in a research note that it sees the CRL as a positive factor for the company’s Amtagvi’s near-term competitive position in post-checkpoint melanoma. However, it also added that more direct competition from cell therapies “could be on the horizon” in 2027.

For additional reference, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported a 30% quarterly revenue growth in its fiscal Q4 and full year 2025 results, driven by Amtagvi demand. Management also reported that gross margin rose to 50%, while fiscal year 2025 revenue of $264 million attained annual guidance.

Iovance Biotherapeutics (NASDAQ:IOVA) is a biopharmaceutical company that develops and commercializes cell therapies as novel cancer immunotherapy products. The company’s lead product candidate is LN-144, which is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for metastatic melanoma.

3. MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) is one of the best stocks under $5 with huge upside potential. Mizuho cut the price target on MannKind Corporation (NASDAQ:MNKD) to $8 from $10 on April 13 and reaffirmed an Outperform rating on the shares. The firm adjusted price targets and estimates for a number of stocks under its coverage in the medical devices and diagnostics group ahead of its fiscal Q1 earnings.

MannKind Corporation (NASDAQ:MNKD) also received a rating update from Truist on April 8. The firm cut the price target on the stock to $6 from $7, reiterating a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings in Biotech, with the firm telling investors in the research note that reactivity to regulatory and policy shifts across the sector is continuing to ease. Truist also stated that it is seeing a recent pickup in deal activity, which holds the potential to build momentum through the remainder of the year into midterms.

The firm sees a robust catalyst path for MannKind Corporation (NASDAQ:MNKD), which could spark momentum for shares, with peds Afrezza label expansion PDUFA set for May 29, 2026, Furoscix ReadyFlow autoinjector PDUFA on July 26, and developmental updates for MNKD-201 in IPF – Part 1 of the phase 1b INFLO study expected to be completed this month.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

2. Genius Sports Ltd. (NYSE:GENI)

Genius Sports Ltd. (NYSE:GENI) is one of the best stocks under $5 with huge upside potential. Stifel cut the price target on Genius Sports Ltd. (NYSE:GENI) to $5 from $7 on April 9, reaffirming a Hold rating on the shares. The rating update came ahead of fiscal Q1 earnings, with the firm updating models for pure-play online sports betting and iCasino operators, as well as data/tech providers.

For additional reference, in its fiscal Q4 and full year 2025 results, Genius Sports Ltd. (NYSE:GENI) reported group revenue of $240.5 million for the quarter and $669.5 million in the full year 2025, reflecting a growth of 37% and 31% year-over-year, respectively. The company also reaffirmed its standalone 2026 guidance of approximately $810-820 million in Group Revenue and $180-190 million in Group Adj. EBITDA.

Genius Sports Ltd. (NYSE:GENI) further reported that after giving effect to the acquisition of Legend, it anticipates the combination to attain around $1.1 billion in Group Revenue, $320-330 million in Group Adj. EBITDA with 50% Free Cash Flow conversion on a 2026 annualized pro forma basis.

Genius Sports Ltd. (NYSE:GENI) provides scalable, technology-led products and services to the sports, sports betting, and sports media industries.

1. UWM Holdings Corporation (NYSE:UWMC)

UWM Holdings Corporation (NYSE:UWMC) is one of the best stocks under $5 with huge upside potential. Keefe Bruyette cut the price target on UWM Holdings Corporation (NYSE:UWMC) to $5 from $6 on April 10, reiterating a Market Perform rating on the shares. UWM Holdings Corporation (NYSE:UWMC) also received a rating update from Barclays on April 6. The firm cut the price target on the stock to $5 from $6, and maintained an Overweight rating on the shares. Barclays told investors in a research note that it adjusted mortgage finance targets as part of a fiscal Q1 earnings preview, adding that higher rates have reset valuations lower.

The firm also said that despite a 40 basis point increase from the February trough for the 30-year fixed-rate mortgage, it is only modestly higher when compared to the start of the year. It sees positive risk/rewards at current valuations for the mortgage origination-levered stocks.

In a separate development, UWM Holdings Corporation (NYSE:UWMC) updated its outlook for fiscal Q1 and full year 2026 on March 9, stating that the company’s total loan origination volume was $49.6 billion for fiscal Q4 2025. This represents its highest quarterly origination volume since 2021.

UWM Holdings Corporation (NYSE:UWMC) also stated that its investments in AI are now implemented and working in various areas, and it is confident in handling two to three times its current volume while avoiding the need to replace team members who depart through natural attrition.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.